SUTRO BIOPHARMA, INC.STROEarnings & Financial Report
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...
STRO Q3 2025 Key Financial Metrics
Revenue
$9.7M
Gross Profit
N/A
Operating Profit
$-48.5M
Net Profit
$-56.9M
Gross Margin
N/A
Operating Margin
-499.9%
Net Margin
-586.6%
YoY Growth
13.8%
EPS
$-0.67
Financial Flow
SUTRO BIOPHARMA, INC. Q3 2025 Financial Summary
SUTRO BIOPHARMA, INC. reported revenue of $9.7M for Q3 2025, with a net profit of $-56.9M (-586.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $9.7M |
|---|---|
| Net Profit | $-56.9M |
| Gross Margin | N/A |
| Operating Margin | -499.9% |
| Report Period | Q3 2025 |
SUTRO BIOPHARMA, INC. Annual Revenue by Year
SUTRO BIOPHARMA, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $62.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $62.0M |
| 2023 | $153.7M |
| 2022 | $67.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $113.7M | $13.0M | $25.7M | $8.5M | $14.8M | $17.4M | $63.7M | $9.7M |
| YoY Growth | 1217.4% | 2.6% | 146.9% | -49.7% | -87.0% | 33.8% | 148.0% | 13.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $470.7M | $403.4M | $489.0M | $451.8M | $387.2M | $321.4M | $262.4M | $209.7M |
| Liabilities | $321.1M | $305.4M | $336.9M | $340.6M | $342.6M | $347.2M | $294.5M | $296.9M |
| Equity | $149.6M | $98.0M | $152.2M | $111.2M | $44.6M | $-25.8M | $-32.1M | $-87.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $14.1M | $-64.7M | $9.5M | $-64.5M | $-71.7M | $-67.9M | $-44.7M | $-38.2M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M